Библиографическая ссылка:
Moorkens E., Godman B., Huys I., Hoxha I., Malaj A., Keuerleber S., Stockinger S., Dimitrova M., Tachkov K., Voncina L., Palcevski V.V., Achniotou G., Slabý J., Popelková L., Kohoutová K., Bartels D., Laius O., Martikainen J.E., Selke G., Kourafalos V., Magnusson E., Einarsdóttir R., Adams R., Joppi R., Allocati E., Jakupi A., Viksna A., Greičiūtė-Kuprijanov I., Bonanno P.V., Suttorp V., Melien O., Plisko R., Mardare I., Мешков Д.О., Novakovic T., Furst J., Zara C., Markovic-Pekovic V., Befrits G., Puckett R., Vulto A.G., Mortenhuber S. The expiry of Humira® market exclusivity and the entry of Adalimumab biosimilars in Europe: An overview of pricing and national policy measurese // Frontiers in Pharmacology. 2021. т 11. С. 1-17 https://www.frontiersin.org/articles/10.3389/fphar.2020.591134/full.